<DOC>
	<DOCNO>NCT00674193</DOCNO>
	<brief_summary>This laboratory study evaluate well dactinomycin vincristine work treat young patient cancer . Studying sample blood urine laboratory patient cancer may help doctor learn dactinomycin vincristine affect body patient respond treatment .</brief_summary>
	<brief_title>Evaluating Dactinomycin Vincristine Young Patients With Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To characterize pharmacokinetics ( PKs ) dactinomycin infant , child , adolescent cancer . II . To identify demographic physiological factor determinant dactinomycin disposition . III . To characterize PKs vincristine ( VCR ) infant , child , adolescent cancer . IV . To identify demographic physiological factor determinant VCR disposition . SECONDARY OBJECTIVES : I . To examine correlation dactinomycin VCR systemic exposure metric toxicity outcomes . II . To explore PK , pharmacodynamic , pharmacogenetic relationship dactinomycin VCR child cancer . OUTLINE : This multicenter study . Patients undergo blood urine collection prior , periodically , treatment dactinomycin vincristine pharmacokinetic , pharmacodynamic , pharmacogenetic analysis . Samples analyze use liquid chromatography-tandem mass spectrometry assay . Genomic DNA extract peripheral blood mononuclear cell isolate analyzed polymerase chain reaction genotyping assay genetic variation gene relevant pharmacology dactinomycin vincristine . After final pharmacokinetic sample collect , patient follow 6 month .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Wilms Tumor</mesh_term>
	<mesh_term>Rhabdomyosarcoma , Embryonal</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive , Peripheral</mesh_term>
	<mesh_term>Dactinomycin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Diagnosis cancer , include , limited , follow : Acute lymphoblastic leukemia Ewing sarcoma Rhabdomyosarcoma Soft tissue sarcoma Wilms tumor Due receive receive dactinomycin and/or vincristine component cancer treatment another clinical trial Able comply study requirement Other concurrent chemotherapeutic agent allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>